Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and …
Over the last 12 months, insiders at Acurx Pharmaceuticals, Inc. have bought $0 and sold $0 worth of Acurx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Acurx Pharmaceuticals, Inc. have bought $149,611 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,161 shares for transaction amount of $24,979 was made by Sailer Carl (director) on 2021‑11‑23.
2021-11-23 | director | 5,161 0.0628% | $4.84 | $24,979 | -21.67% | |||
2021-11-19 | 5,034 0.0595% | $4.90 | $24,672 | -24.69% | ||||
2021-11-19 | President and CEO | 5,200 0.0602% | $4.80 | $24,960 | -24.69% | |||
2021-06-29 | director | 12,500 0.1719% | $6.00 | $75,000 | -30.67% |
DELUCCIA ROBERT J | 1031461 6.106% | $0.83 | 1 | 0 | <0.0001% | |
LUCI DAVID P | President and CEO | 1008723 5.9714% | $0.83 | 1 | 0 | <0.0001% |
Sailer Carl | director | 73078 0.4326% | $0.83 | 2 | 0 | <0.0001% |
The Vanguard Group | $1.2M | 3.1 | 491,687 | +20.99% | +$208,984.97 | <0.0001 | |
Geode Capital Management | $285,105.00 | 0.73 | 116,352 | +3.76% | +$10,340.55 | <0.0001 | |
Advisor Group Holdings Inc | $140,262.00 | 0.36 | 57,250 | 0% | +$0 | <0.0001 | |
State Street | $106,492.00 | 0.27 | 43,466 | +52.16% | +$36,505.10 | <0.0001 | |
LINSCO PRIVATE LEDGER CORP | $98,576.00 | 0.25 | 40,235 | +194.12% | +$65,059.92 | <0.0001 |